Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
-$0.10 today
- Market cap
- $99.30M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
Volume 4.42M
Average 17.46M
OTLK EBITDA Margin
EBITDA as a percentage of revenue.
Outlook Therapeutics, Inc.NASDAQ: OTLK
EBITDA Margin · Q2 FY2026 · quarter ended Mar 2026
EBITDA Margin at -10983.0%
EBITDA Margin was -10983.0% in Q2 FY2026. On a trailing-twelve-month basis it was -18634.1%, down 28166.9 pp year over year.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -1477.9% for the fiscal year ending Sep 2026, up from -4497.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -10983.0%-12096.8 pp QoQ
- Last fiscal yearSep 2025
- -4497.7%— YoY
- LTMMar 2026
- -18634.1%-28166.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | +203.3 pp | — |
| 1 year | — | +3019.8 pp | — |
| 3 years | — | +4505.6 pp | — |
| 5 years | +4503.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -4497.7%
- Year-over-year change
- —
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | -4497.7% | — |
| FY2024 | 2024-09-30 | — | — |
| FY2023 | 2023-09-30 | — | — |
| FY2022 | 2022-09-30 | — | — |
| FY2021 | 2021-09-30 | — | — |
EBITDA Margin vs competitors
How OTLK compares with its peers on the latest reported figures
- OTLK's LTM Mar 2026 EBITDA Margin of -18634.1% is the lowest of the 6 companies compared; the peer median is -104.8%.
- Its year-over-year change of -28166.9 pp is the lowest of 4, against a peer median of +1695.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 3.2% | +1695.0 pp | +2334.4 pp | |
| LTM Mar 2026 | -48.4% | +416.8 pp | +3974.4 pp | |
| LTM Jun 2026 | -104.8% | — | — | |
| LTM Mar 2026 | -769.0% | +15034.6 pp | — | |
| LTM Mar 2026 | -1017.5% | — | — | |
| LTM Mar 2026 | -18634.1% | -28166.9 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
OSTXOS Therapies Incorporated | FY2025 | — | — | — |
| Peer median (excluding OTLK) | -104.8% | +1695.0 pp | +3154.4 pp | |
Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.41M |
| Cost of Revenue | 262.14K | 204.69K | 44.19K | 113.86K | 756.33K |
| Gross Profit | (262.14K) | (204.69K) | (44.19K) | (113.86K) | 657.21K |
| Gross Margin | — | — | — | — | 46.5% |
| Research & Development | 38.96M | 42.33M | 26.45M | 41.76M | 27.18T |
| Selling, General & Admin | 12.77M | 20.74M | 26.67M | 29.94M | 39.94M |
| Operating Expenses | 51.73M | 62.87M | 53.13M | 71.7M | 67.72M |
| Depreciation & Amortization | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K |
| EBITDA | (51.51M) | (64.36M) | (57.38M) | (72.09M) | (63.58M) |
| EBITDA Margin | — | — | — | — | -4497.7% |
| Operating Income | (51.73M) | (63.07M) | (53.13M) | (71.7M) | (67.06M) |
| Operating Margin | — | — | — | — | -4744.3% |
| Interest Income | 0 | 0 | 0 | 906.15K | 89.74K |
| Interest Expense | 936.13K | 1.49M | 1.56M | 3.16M | 283.13K |
| Other Income / Expenses | (1.43M) | (2.98M) | (5.85M) | (3.66M) | 3.08M |
| Income Before Tax | (53.16M) | (66.05M) | (58.98M) | (75.36M) | (63.98M) |
| Pre-Tax Margin | — | — | — | — | -4526.0% |
| Income Tax Expense | 2K | 2.8K | 2.8K | 2.8K | (1.55M) |
| Net Income | (53.16M) | (66.05M) | (58.98M) | (75.37M) | (62.42M) |
| Net Margin | — | — | — | — | -4416.2% |
| EPS (Basic) | (6.96) | (6.23) | (4.72) | (4.06) | (1.79) |
| EPS (Diluted) | (6.96) | (6.23) | (4.72) | (4.06) | (1.79) |
| Weighted Avg Shares | 7.63M | 10.6M | 12.51M | 18.55M | 34.8M |
| Weighted Avg Shares (Diluted) | 7.63M | 10.6M | 12.51M | 18.55M | 25.48M |
Outlook Therapeutics, Inc.
NASDAQ:OTLK
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.